Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vibha Sharma

Vibha Sharma is a senior reporter covering pharmaceutical and medtech regulatory developments across the globe. She joined Scrip Regulatory Affairs in September 2010 and has since then been at the center of deciding and writing news on important regulatory issues affecting the pharma and medtech sectors and explaining their implications for the industry.

Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.

Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.

Set Alert for Articles By Vibha Sharma

Latest From Vibha Sharma

EU Guide To Tackle Inconsistent Reporting Of Reference Safety Info In Trials

An EU guideline on the complex subject of how drug sponsors should present and manage the reference safety information in their clinical trial applications is nearing finalization. For the past several months, drug companies have been grappling with an increased regulatory focus on RSI, which has resulted in their trial applications being rejected or studies being significantly delayed.

Clinical Trials Safety

Betting On A Brexit Transition Period Is A Gamble: EMA Warning For Industry

A senior official at the European Medicines Agency has warned pharmaceutical companies are taking a risk by endlessly waiting to get news on whether there would be a Brexit transition period. Drug makers still waiting to prepare for changes that may be needed once the UK leaves the EU were told 'this is your risk and your decision.'

Brexit Regulation

Global Medtech Guidance Tracker: September 2017

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight new guidance documents were posted to the tracker.

Regulation Singapore

Pharma Buoyed By Preview Of 'Helpful Changes' To EMA's Signal Management Guide

The European Medicines Agency is revising its signal management guideline to clarify several terminologies and offer flexibility to help companies comply with their legal obligation to monitor the revamped EudraVigilance database. The biggest relief for the industry is that the new procedures in the guideline will be initially tested on a small number of products.

Safety Post Market Regulation & Studies

EudraVigilance Update Needs 10-Day IT Shutdown At EMA; Interim ADR Reporting Plans In Place

The European Medicines Agency is having to shut down some of its systems for two weeks in order to have the revamped EU pharmacovigilance database up and running for 9am on Nov. 22. The shutdown will affect the reporting of adverse drug reactions as well as some aspects of other processes such as submission of periodic safety reports and marketing authorization applications. Companies will have to be vigilant as arrangements will vary from country to country.

Safety Post Market Regulation & Studies

Global Pharma Guidance Tracker – September 2017

Stay up to date on regulatory guidelines from around the world, with the Pink Sheet's Guidance Tracker.

Regulation BioPharmaceutical
See All